EcoDrugPlus

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSAPOG00000001968
Gene Symbol: CHRM3
3 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSAPOG00000004911
Gene Symbol: CHRM3
3 Cross references
188 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSAPOG00000019679
Gene Symbol: CHRM4
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSAPOG00000020895
Gene Symbol: CHRM5
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSAPOG00000008095
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSAPOG00000019588
Gene Symbol: CHRNB2
1 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSAPOG00000008023
Gene Symbol: CHRNB4
3 Cross references
194 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSAPOG00000005738
Gene Symbol: CHRM5B
1 Cross references
190 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSAPOG00000024353
Gene Symbol: F2R
3 Cross references
211 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSAPOG00000007914
Gene Symbol: F3
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSAPOG00000020181
Gene Symbol: LOC110970379
3 Cross references
203 Possible Orthologues:

Coagulation Factor X-Like

Ensembl ID : ENSAPOG00000020405
Gene Symbol: LOC110971743
3 Cross references
241 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).